查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2009213

醫藥和醫療設備組合產品的市場規模、佔有率、趨勢和預測：按產品、應用、最終用戶和地區分類，2026-2034 年

Drug Device Combination Products Market Size, Share, Trends and Forecast by Product, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2025年全球醫藥及醫療設備（PHEV）複合體市場規模為1,764億美元。展望未來，IMARC Group預測該市場將在2026年至2034年間以5.92%的複合年成長率成長，到2034年達到3,006億美元。目前，北美市場主導地位，預計2025年將佔據41.7%的市場。北美市場的主導地位得益於其完善的醫療保健基礎設施、健全的法規結構以及對研發活動的大量投入。先進的技術創新、高額的醫療費用支出以及對改善患者療效日益成長的關注，都將進一步推動醫療設備複合體市場佔有率的擴張。

醫藥醫療設備組合產品的市場趨勢：

藥物輸送系統的技術進步

新型藥物輸送系統，例如自動注射器、吸入器和輸液泵，正在改變我們給藥的方式，使治療更加精準、便利和有效。這些系統能夠實現標靶給藥，幫助患者達到預期的治療效果，同時最大限度地降低副作用風險。例如，自動注射器正在革新日常用藥管理，使患者能夠輕鬆舒適地自行用藥，從而提高患者的自主性。此外，吸入器和輸液幫浦等設備能夠提供高度可控且穩定的藥物輸送，這對於慢性病管理尤其重要。山德士公司於2025年推出的Pyzchiva®是首個在歐洲上市的Ustekinumab單抗生物相似藥自動注射器，標誌著藥物自我給藥方式向先進方向的轉變。該設備旨在提高舒適性和便利性，同時也有助於提高患者的用藥依從性，尤其是在治療慢性發炎性疾病方面。因此，這些創新不僅正在改變患者照護的方式，也正在推動藥品和醫療設備組合的市場成長。

慢性病盛行率增加

心血管疾病、糖尿病和癌症等慢性疾病的日益流行，是推動個人化創新藥物和醫療設備組合需求成長的主要動力，這些組合旨在滿足複雜的治療需求。產業報告顯示，在美國，十分之六的人至少患有一種慢性疾病，十分之四的人患有兩種或兩種以上慢性疾病。死亡率統計數據凸顯了這些疾病對全球人口的廣泛影響。例如，澳洲健康與福利研究所 (AIHW) 報告稱，47% 的人口至少患有一種慢性疾病，20% 的人口患有兩種或兩種以上慢性疾病。慢性疾病盛行率的不斷上升凸顯了對能夠提供標靶有效治療的創新醫療解決方案的需求，從而推動了對藥物和醫療設備組合的市場需求。對高效個人化治療的持續需求，凸顯了這些醫療領域進步的重要性。

人口老化的過程

全球人口老化和預期壽命的延長給老年醫學帶來了嚴峻挑戰，推動了對先進醫療解決方案（例如藥物-醫療設備組合）的需求。世界衛生組織（世衛組織）預測，到2030年，六分之一的人口將超過60歲，老年人口將達到14億。到2050年，全球60歲以上人口預計將達到21億，80歲以上人口將增加至4.26億，是2020年的三倍。這些人口結構的變化迫切需要開發更有效的治療方案來應對與老齡化相關的健康問題，從而增加了對創新藥物-醫療設備組合的需求，這些組合能夠提供有效的治療，提高患者的依從性，並帶來更佳的健康結果。因此，在針對全球老齡化人口的客製化解決方案日益成長的需求驅動下，藥物-醫療設備組合市場的前景依然十分光明。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：醫藥和醫療設備複雜產品的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品分類

  • 藥物釋放型支架
  • 經皮吸收貼劑
  • 點滴幫浦
  • 藥物釋放型球囊
  • 吸入器
  • 其他

第7章 市場區隔：依應用領域分類

  • 循環系統
  • 糖尿病
  • 癌症治療
  • 呼吸系統疾病
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院
  • 門診手術中心
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Abbott Laboratories
    • Baxter International Inc.
    • Bayer AG
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Medtronic plc
    • Novartis AG
    • Smith & Nephew plc
    • Stryker Corporation
    • Terumo Corporation
Product Code: SR112026A4751

The global drug device combination products market size was valued at USD 176.4 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 300.6 Billion by 2034, exhibiting a CAGR of 5.92% from 2026-2034. North America currently dominates the market, holding a market share of 41.7% in 2025. The dominance of the segment is attributed to its well-established healthcare infrastructure, strong regulatory frameworks, and high investment in research activities. Advanced technological innovations, significant healthcare expenditure, and a growing focus on improving patient outcomes, are further contributing to the expansion of the drug device combination products market share.

DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS:

  • Major Market Drivers: As per the drug device combination products market analysis, the rising prevalence of chronic diseases and the requirement for more efficient and convenient treatment alternatives are propelling the demand for drug-device combination products. The drug device combination products market growth is also stimulated by the burgeoning geriatric population worldwide, which has surged the demand for new healthcare approaches, as elderly people are producing more lifestyle-related health problems. Additionally, companies have increasingly adopted approaches to personalized medicine, including drug delivery gadgets for targeted therapy, which is further positively contributing to the drug device combination products market share. Other factors that have fueled the drug device combination products market outlook include regulatory support and economic incentives for combination product development, as well as expanding healthcare spending in developing countries.
  • Key Market Trends: As per the drug device combination products market research, the most substantial trends in the drug-device combination products are the growing interest in wearable drug delivery devices for the patient's mobility and quality of life improvement. Another factor that propels the drug device combination products market value is the increasing use of smart devices to control patient adherence and therapy response and adjust the dose and treatment regime as necessary in real-time. In line with this, the incorporation of digital technology into products and their ability to utilize the Internet of Things (IoT) increases patient engagement and outcomes monitoring, which is further driving the drug device combination products market demand. Apart from this, as per the drug device combination products market forecast, the progression of three-dimensional (3D) printing technology is projected to create new opportunities for individualizing device manufacturing based on patient anatomy and needs.
  • Geographical Trends: As per the drug device combination products market research report, North America is the leading region in the industry due to the developed healthcare infrastructure, extensive investment in research and development (R&D), and lenient regulation. Besides this, the high health expenditure supported by the massive burden of diseases in the region has driven adoption of new and emerging treatment alternatives, which is further accelerating the drug device combination products market price. Europe is a close follower in the drug device combination products market segmentation, given its strong healthcare systems and focus on quality and safety. On the other hand, the Asia-Pacific region is an increasingly growing market supported by rising health expenditure, increasing knowledge of modern treatment approaches, and a growing number of chronic conditions, which is further boosting the drug device combination products market revenue.
  • Competitive Landscape: As per the drug device combination products market statistics, some of the key players in the market include Abbott Laboratories, Baxter International Inc., Bayer AG, Becton Dickinson and Company, Boston Scientific Corporation, GlaxoSmithKline plc, Johnson & Johnson, Medtronic plc, Novartis AG, Smith & Nephew plc, Stryker Corporation, Terumo Corporation, etc.
  • Challenges and Opportunities: As per the drug device combination products market overview, the market has many challenges, including the high level of regulatory requirements, which can lead to an increase in development time and as a result, increase the cost. Ensuring the compatibility of the drug and device, which must meet all safety and effectiveness standards, is a big difficulty. Many of the same factors present opportunities for innovation. In particular, new approaches to increasing the efficiency of devices and increasing the convenience for the patient. A favorable opportunity is also to replenish the market for countries with a potential demand for advanced medical solutions that are not being solved.

Regulatory agencies are progressively offering clear routes for the approval and market entry of drug-device combination products, promoting investment in the creation of these solutions. Supportive regulatory environments enable innovative products to access the market more effectively, contributing to the market growth. Additionally, drug-device combination products are intended to be easy to use, simplifying the process of administering medication. This user-friendliness and the convenience of self-administration result in improved patient compliance with treatment plans, an essential element for the long-term management of chronic illnesses. Furthermore, ongoing advancements in medical devices and drug delivery technologies are improving the performance and efficacy of combination products. Innovative drug delivery methods, including auto-injectors and infusion pumps, provide more accurate, convenient, and effective treatment choices, resulting in higher patient satisfaction.

The United States is a crucial segment in the market, propelled by continuous technological advancements in medical devices and pharmaceuticals. Developments in drug delivery methods, such as auto-injectors and infusion pumps, are enhancing the efficiency and ease of use of drug-device combination products. For instance, in 2025, the FDA authorized SPN-830 (Onapgo), the initial subcutaneous apomorphine infusion device for Parkinson's disease, enabling continuous delivery to minimize motor fluctuations and OFF time, further enhancing treatment choices. Besides this, the robust healthcare system and significant funding in medical research in the country are leading to the creation of sophisticated drug-device combination products.

DRUG DEVICE COMBINATION PRODUCTS MARKET TRENDS:

Technological Advancements in Drug Delivery Systems

New drug delivery systems, including auto-injectors, inhalers, and infusion pumps, are transforming healthcare administration, making treatments more precise, convenient, and effective. These systems enable targeted drug delivery, allowing patients to achieve the desired therapeutic outcomes while minimizing the risk of adverse drug reactions. Auto-injectors, for instance, have revolutionized daily medication management by enabling patients to administer their own treatments easily and comfortably, thereby improving patient autonomy. Additionally, devices like inhalers and infusion pumps offer highly controlled and consistent drug delivery, which is especially critical for managing chronic conditions. The launch of Pyzchiva(R) by Sandoz in 2025, the first ustekinumab biosimilar auto-injector commercially available in Europe, highlights this shift toward enhanced self-administration. The device, designed to improve comfort and convenience, also boosts patient adherence, particularly in treating chronic inflammatory diseases. As a result, these innovations are not only reshaping patient care but also supporting the drug device combination products market growth.

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic illnesses, including cardiovascular diseases (CVDs), diabetes, and cancer, is a major factor driving the need for personalized and innovative drug-device combination products designed for intricate therapeutic requirements. Industry reports indicate that 6 in 10 individuals in America have at least one chronic disease, and 4 in 10 have two or more chronic diseases. Mortality statistics emphasize the extensive influence of these conditions on populations worldwide. In Australia, for example, the Australian Institute of Health and Welfare indicates that 47% of the people have at least one chronic illness, while 20% deal with two or more chronic diseases. The increasing prevalence of chronic diseases underscores the necessity for innovative medical solutions that can provide focused, effective treatment delivery, thus driving the drug-device combination products market demand. The continuous need for efficient, customized treatments highlights the significance of these advancements in the medical field.

Rising Geriatric Population

The worldwide growth of the elderly population and the increase in life span pose major obstacles in gerontology, leading to a higher need for sophisticated medical solutions, such as drug-device combination products. The World Health Organization (WHO) states that by 2030, one out of every six people will be 60 years or older, resulting in an elderly population of 1.4 billion. By 2050, it is anticipated that the worldwide population of individuals aged 60 and older will reach 2.1 billion, while those aged 80 and above are expected to grow to 426 million, which is three times the figure noted in 2020. This change in demographics requires creating more efficient treatment solutions to address age-related issues, fostering the need for innovative drug-device combinations that provide better treatment delivery, patient adherence, and superior health outcomes. As a result, the drug-device combination products market outlook remains highly positive, driven by the growing demand for tailored solutions for the aging global population.

DRUG DEVICE COMBINATION PRODUCTS INDUSTRY SEGMENTATION:

Analysis by Product:

  • Drug Eluting Stents
  • Transdermal Patches
  • Infusion Pumps
  • Drug Eluting Balloon
  • Inhalers
  • Others

Transdermal patches dominate the market with 24.2%, accredited to their capacity to ensure controlled and reliable drug delivery for a prolonged duration. This approach enhances patient adherence by removing the requirement for regular dosing or invasive interventions. The non-intrusive characteristics of transdermal patches enhance patient comfort and lower the likelihood of complications linked to oral medications or injections. Moreover, transdermal patches benefit drugs that experience considerable first-pass metabolism in the liver by circumventing the gastrointestinal system, resulting in enhanced drug absorption. Their simple application and subtle nature also make them a favored option for chronic conditions, enabling patients to handle their treatment plan without interfering with everyday life. Additionally, continuous improvements in patch design and technology are increasing the adaptability and efficacy of transdermal systems. The latest drug device combination products market trends highlight a rising demand for transdermal patches, driven by their ability to provide convenient, effective, and non-invasive treatment options, particularly in the management of chronic diseases.

Analysis by Application:

  • Cardiovascular
  • Diabetes
  • Cancer Treatment
  • Respiratory Diseases
  • Others

Respiratory diseases hold the biggest market share attribute to the widespread occurrence of issues like asthma, chronic obstructive pulmonary disease (COPD), and various other chronic respiratory disorders. These conditions necessitate ongoing management, increasing the need for effective treatments that offer steady relief and enhance patients' quality of life. The intricate nature of respiratory disorders frequently requires sophisticated drug delivery methods, rendering combination products especially advantageous. The growing recognition of respiratory health, along with a heightened global burden of pollution and lifestyle influences, also leads to the higher prevalence of these conditions. As a result, healthcare practitioners are focusing on creating advanced treatments and delivery systems specifically for respiratory care, promoting improved patient results. In addition, respiratory illnesses frequently necessitate accurate and effective drug delivery, and combination products provide the benefit of targeted therapy, reinforcing their prominence in the market.

Analysis by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Hospitals represent the largest segment, accounting 48.7% market share, owing to their essential function in the healthcare system, where many patients with complicated conditions need urgent and specialized treatment. Hospitals feature modern medical facilities, enabling the provision of state-of-the-art therapies, such as drug-device combination products. Consistent monitoring and tailored treatment plans in hospitals encourage the implementation of innovative therapies that enhance patient outcomes. Furthermore, hospitals frequently act as centers for clinical trials, promoting the rapid incorporation of new technologies and products into clinical practice. The concentration of healthcare practitioners and resources in hospitals allows for the efficient and effective use of combination products, guaranteeing their correct administration and oversight. Additionally, with the global rise in the demand for healthcare services, hospitals remain the main setting for addressing critical conditions, reinforcing their leading role in the market for drug-device combination products.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market with a share of 41.7%, because of its developed healthcare system, strong regulatory framework, and significant investment in research activities. The region benefits from a robust healthcare system that encourages the extensive use of advanced medical technologies. Significant healthcare expenditure facilitates the swift launch of new drug-device combination products, bolstering the region's dominance in market expansion. Moreover, North America is home to prominent pharmaceutical and medical device firms, promoting ongoing innovation and the advancement of next-generation treatments. Furthermore, investment in advanced manufacturing capabilities to support the development and commercialization of drug-device combination products is ensuring improved production efficiency. In 2024, PCI Pharma Services announced a $365 million investment in its US and EU facilities to support the clinical and commercial assembly of advanced drug delivery and drug-device combination products. Key projects included expansions in Rockford (Illinois), Philadelphia, and Dublin. These developments aimed to enhance PCI's global capabilities in injectable formats and patient-centric packaging.

KEY REGIONAL TAKEAWAYS:

UNITED STATES DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS

In North America, the market portion held by the United States is 86.80% owing to scientific advancements and the increased demand for focused therapies. Swift progress in materials science and microfabrication is paving the way for advanced delivery systems, including drug-eluting stents, inhalers, and implantable insulin pumps, which enhance dosage accuracy, patient compliance, and treatment results. Producers are increasingly utilizing biocompatible polymers, nanoparticle carriers, and intelligent sensors to develop integrated systems that enable sustained or on-demand medication delivery. Additionally, clear regulations concerning combination products are simplifying approval processes, fostering investment and innovation. Furthermore, the growing incidence of chronic illnesses like heart disease, diabetes, and cancer is catalyzing the demand for less invasive and more convenient treatment choices. As per the American Heart Association, nearly 48.6% of people in the United States experience various forms of cardiovascular disease, such as high blood pressure and coronary heart disease. The International Diabetes Federation stated that in 2024, 38.5 million people in the United States experienced diabetes. Besides this, payer systems and healthcare providers are emphasizing value-based care, promoting solutions that can reduce hospitalization rates and enhance long-term health results. Strategic alliances between pharmaceutical companies, medtech firms, and contract development organizations are accelerating product pipelines, allowing quicker market launch of combination products.

EUROPE DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS

The expansion of the Europe drug device combination products market is primarily driven by a rising need for home healthcare and self-administration therapies, necessitating dependable and easy-to-use delivery systems. The movement towards outpatient care and initiatives to shorten hospital stays is increasing the use of wearable drug delivery devices, including infusion pumps and auto-injectors, allowing patients to handle their treatments with greater independence. Innovations in drug delivery systems, along with a growing emphasis on personalized medicine, are leading to the creation of more advanced and user-friendly combination products. Moreover, increasing awareness among healthcare professionals and patients regarding the advantages of these products, including enhanced compliance, targeted delivery, and minimized side effects, is bolstering the market growth. The regulatory landscape in Europe is adapting to these intricate products, promoting investment and innovation from companies in pharmaceuticals and medical devices. For example, in January 2025, the UK Government reintroduced the Innovative Licensing and Access Pathway (ILAP) for pharmaceuticals. The ILAP plan seeks to reduce the time to market for innovative and transformative medications and drug-device combination products by providing drug researchers with tailored and coordinated support from the ILAP Partners right from the start of clinical development.

ASIA PACIFIC DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS

The Asia Pacific market for drug-device combination products is growing because of swift urbanization, heightened healthcare awareness, and improved access to medical technologies in developing countries. An expanding middle-class demographic with enhanced healthcare expenditures is driving the need for innovative treatment options, such as combination products that provide convenience and effectiveness. Government efforts to enhance healthcare infrastructure and encourage local production of pharmaceuticals and medical equipment are further contributing to the market growth. Moreover, the rising prevalence of chronic illnesses like asthma, cancer, and heart diseases is generating a continuous demand for precise and effective treatments, especially those suitable for self-administration. In 2023, the Press Information Bureau (PIB) reported more than 1,400,000 cancer cases in India. The Global Asthma Report states that roughly 35 million people in India were affected by asthma in 2022. In addition, the growing use of minimally invasive treatment techniques and the incorporation of digital health technologies into drug delivery systems are improving patient outcomes and fueling innovation.

LATIN AMERICA DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS

The market for drug-device combination products in Latin America is influenced by rising investments in healthcare infrastructure and the growth of insurance coverage, enhancing patient access to innovative therapies. Increasing urbanization and shifts in lifestyle are resulting in higher cases of ailments like diabetes and respiratory conditions, driving the need for effective drug delivery methods. For example, according to the International Diabetes Federation (IDF), the count of people with diabetes in Brazil hit 16.6 million in 2024. This figure is projected to rise to 24.0 Million by 2050. Furthermore, the area is experiencing increased cooperation among pharmaceutical and medical device firms to create innovative combination products suited to regional demands. Government efforts aimed at enhancing regulatory systems and accelerating product approvals are further aiding quicker penetration across Latin America. The drug device combination products market forecast for Latin America indicates significant growth as these factors continue to shape the demand for advanced therapies and delivery systems.

MIDDLE EAST AND AFRICA DRUG DEVICE COMBINATION PRODUCTS MARKET ANALYSIS

The drug device combination products market in the Middle East and Africa is seeing growth driven by rising healthcare investments and expanding government initiatives focused on enhancing healthcare infrastructure and accessibility. For example, the Saudi Arabian Government assigned SR 99,279,673 to the Ministry of Health (MoH) for FY 2025, showing a notable rise compared to FY 2024, which was SR 86,253,063. Moreover, enhancing local pharmaceutical manufacturing capabilities is improving the availability of combination products designed for regional healthcare requirements. The growing recognition of preventive healthcare and early detection is encouraging the adoption of combination treatments for chronic and lifestyle-related conditions. Additionally, collaborations between public sectors and private companies are enhancing distribution systems, guaranteeing broader access to these products, including in rural and marginalized regions.

COMPETITIVE LANDSCAPE:

Major participants in the drug-device combination products market are concentrating on innovation and broadening their product ranges to address the increasing need for tailored and effective treatment options. They are making significant investments in research operations to advance drug delivery systems, upgrade device capabilities, and achieve improved patient outcomes. Strategic alliances and collaborations are being established to utilize technological advancements and speed up product development. Furthermore, ensuring regulatory adherence and tackling patient safety issues continue to be key priorities. In 2025, OneSource Specialty Pharma announced that its flagship drug-device combination facility in Bangalore maintained its USFDA compliance status. Following a March 20 to 28, 2025 inspection, the USFDA issued a Form 483 with four observations, later classified as "Voluntary Action Indicated" (VAI). This classification confirms the facility's continued adherence to quality standards.

The report provides a comprehensive analysis of the competitive landscape in the drug device combination products market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Baxter International Inc.
  • Bayer AG
  • Becton Dickinson and Company
  • Boston Scientific Corporation
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Medtronic plc
  • Novartis AG
  • Smith & Nephew plc
  • Stryker Corporation
  • Terumo Corporation

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the drug device combination products market?

2. What is the future outlook of drug device combination products market?

3. What are the key factors driving the drug device combination products market?

4. Which region accounts for the largest drug device combination products market share?

5. Which are the leading companies in the global drug device combination products market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Drug Device Combination Products Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Drug Eluting Stents
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Transdermal Patches
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Infusion Pumps
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Drug Eluting Balloon
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Inhalers
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Cardiovascular
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Diabetes
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cancer Treatment
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Respiratory Diseases
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Baxter International Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Becton Dickinson and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Boston Scientific Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Medtronic plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Smith & Nephew plc
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Stryker Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Terumo Corporation
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Drug Device Combination Products Market: Major Drivers and Challenges
  • Figure 2: Global: Drug Device Combination Products Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Drug Device Combination Products Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Drug Device Combination Products Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Drug Device Combination Products Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Drug Device Combination Products Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Drug Device Combination Products Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Drug Device Combination Products (Drug Eluting Stents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Drug Device Combination Products (Drug Eluting Stents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Drug Device Combination Products (Transdermal Patches) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Drug Device Combination Products (Transdermal Patches) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Drug Device Combination Products (Infusion Pumps) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Drug Device Combination Products (Infusion Pumps) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Drug Device Combination Products (Drug Eluting Balloon) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Drug Device Combination Products (Drug Eluting Balloon) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Drug Device Combination Products (Inhalers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Drug Device Combination Products (Inhalers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Drug Device Combination Products (Other Products) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Drug Device Combination Products (Other Products) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Drug Device Combination Products (Cardiovascular) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Drug Device Combination Products (Cardiovascular) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Drug Device Combination Products (Diabetes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Drug Device Combination Products (Diabetes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Drug Device Combination Products (Cancer Treatment) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Drug Device Combination Products (Cancer Treatment) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Drug Device Combination Products (Respiratory Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Drug Device Combination Products (Respiratory Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Drug Device Combination Products (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Drug Device Combination Products (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Drug Device Combination Products (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Drug Device Combination Products (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Drug Device Combination Products (Ambulatory Surgical Centers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Drug Device Combination Products (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Drug Device Combination Products (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Drug Device Combination Products (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: North America: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: North America: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: United States: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: United States: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Canada: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Canada: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Asia-Pacific: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Asia-Pacific: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: China: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: China: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Japan: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Japan: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: India: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: India: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: South Korea: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: South Korea: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Australia: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Australia: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Indonesia: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Indonesia: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Others: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Europe: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Europe: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Germany: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Germany: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: France: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: France: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: United Kingdom: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: United Kingdom: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Italy: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Italy: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Spain: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Spain: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Russia: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Russia: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Latin America: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Latin America: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Brazil: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Brazil: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Mexico: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Mexico: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Others: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Others: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Middle East and Africa: Drug Device Combination Products Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Middle East and Africa: Drug Device Combination Products Market: Breakup by Country (in %), 2025
  • Figure 84: Middle East and Africa: Drug Device Combination Products Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Global: Drug Device Combination Products Industry: SWOT Analysis
  • Figure 86: Global: Drug Device Combination Products Industry: Value Chain Analysis
  • Figure 87: Global: Drug Device Combination Products Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Drug Device Combination Products Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Drug Device Combination Products Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Drug Device Combination Products Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Drug Device Combination Products Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Drug Device Combination Products Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Drug Device Combination Products Market: Competitive Structure
  • Table 7: Global: Drug Device Combination Products Market: Key Player